Skip to content
Bored Studies
RecruitingPhase 3

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Pfizer · NCT07845500

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
660
US sites recruiting
5
Study start
September 30, 2026
Record last updated
October 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.

Participants will be in the study for about 11 months.

Being studied: Semaglutide; Berobenatide; Tirzepatide

Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Aged ≥18 years.
  • Currently taking semaglutide or tirzepatide for obesity management.

Exclusion Criteria

  • Diagnosis of any form of diabetes.
  • History of acute or chronic pancreatitis.
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Recruiting US locations

Study contacts (from the official record)

  • Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
All weight loss studies in Alabama →
A Study to Learn About Switching to a Monthly Study Medicine… (NCT07845500) | Bored Studies